RMD

ResMed Inc. 10-Q Summary: Period Ended December 31, 1996

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended December 31, 1996, and the six-month period ended December 31, 1996. ResMed Inc. is a Delaware holding company for ResMed Holdings Ltd., an Australian entity that designs, manufactures, and markets devices for the evaluation and treatment of sleep-disordered breathing, primarily obstructive sleep apnea. Principal manufacturing is located in Australia, with major distribution and sales sites in the United States, United Kingdom, and Europe.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Net revenue increased 56% year-over-year for the six-month period, driven by higher unit sales of flow generators and accessories in North America and Europe. European revenue growth was bolstered by the acquisition of the Priess business in February 1996.
• Margin Expansion: Gross margin improved from 51% to 58%, attributed to a shift toward higher-margin products and strong European sales.
• Expense Increases: Selling, general, and administrative (SG&A) expenses rose 75% to $8.1 million, primarily due to an increase in sales and administrative personnel (from 74 to 91) and legal costs. Research and development (R&D) expenses increased 23% to $1.7 million due to new product development and consultant usage.
• Other Income: Other net income surged 63% to $1.8 million, largely due to an $825,000 gain from the realization of foreign currency option contracts. Conversely, government grant income declined as the Australian Federal Government export grants program terminated on June 30, 1996.
• Tax Rate: The effective income tax rate increased to 32% from 28%, primarily due to higher German corporate taxation rates, partially offset by Australian R&D tax deductions.

Outlook, Risks, and Contingencies

Liquidity and Capital Resources: The company maintains strong liquidity with approximately $26.2 million in cash and marketable securities. Working capital increased to $32.3 million. Capital expenditures for the six months totaled $1.4 million, focused on software, hardware, and production tooling.

Legal Proceedings:

• Patent Revocation: A patent held by ResMed was revoked in Australia in 1994; the company has accrued $300,000 for associated costs.
• Respironics Litigation: Ongoing patent infringement disputes with Respironics Inc. in the U.S. and Australia. Respironics has filed counterclaims alleging invalidity and unfair trade practices, seeking approximately $901,000 in damages. Management believes these actions will not have a material adverse effect but acknowledges ongoing legal costs and uncertainty.

Foreign Exchange Risk: The company is exposed to currency fluctuations affecting international sales and manufacturing costs. It manages this risk through foreign currency option contracts with notional amounts totaling $42.6 million as of December 31, 1996.

Investor Verification Checklist

• Verify the sustainability of the 58% gross margin given the shift in product mix and the termination of government export grants.
• Monitor the status and potential financial impact of the ongoing litigation with Respironics Inc., specifically the $901,000 claim in Australia.
• Assess the impact of the Australian R&D tax deduction reduction (from 150% to 125%) on future effective tax rates.
• Review the integration and revenue contribution of the Priess acquisition in the German market.
• Confirm the company's ability to maintain positive operating cash flow as accounts receivable levels rise with increased sales.